Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?
Written by Robert Izquierdo for The Motley Fool -> CEO Jason Coloma sold 32,564 shares in May for a total transaction value of approximately $847,000, at a weighted average price around $26.01 per share. All shares disposed were indirect holdings, with no direct holdings involv
CEO Jason Coloma sold 32,564 shares in May for a total transaction value of approximately $847,000, at a weighted average price around $26.01 per share.
All shares disposed were indirect holdings, with no direct holdings involved in this transaction.
The transaction occurred after a 135.3% one-year share price increase as of May 26, 2026.
Jason Coloma, Chief Executive Officer of Maze Therapeutics (NASDAQ:MAZE) , reported the sale of 32,564 common shares via multiple open-market transactions between May 22 and May 26, 2026, for a total consideration of approximately $847,000, as disclosed in the SEC Form 4 filing .
Transaction value based on SEC Form 4 weighted average reported price ($26.01).
Note: 1-year performance is calculated using May 26, 2026 as the reference date.
Maze Therapeutics is a clinical-stage biopharmaceutical company advancing precision medicines for complex renal and metabolic disorders. The company leverages proprietary genetic insights to develop novel small molecule therapies, with a pipeline anchored by APOL1 and SLC6A19 inhibitor candidates.
The May sale of Maze Therapeutics stock by CEO Jason Coloma comes at a time when shares had dropped from a 52-week high of $53.65 reached in March. The stock price rose due to encouraging clinical trial data, but shares fell after investors began cashing in.
